Ziconotide dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Ziconotide is a pain drug made from cone snail venom, approved in 2004 for severe long-term pain.
Evidence grade for Ziconotide: Moderate. The rule: at least one finished study in people, and at least 100 people who took it. The sum on this page: 2 completed trials, 111 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 111
- Human studies
- 2
- Found nothing
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved on 28 December 2004 under NDA 021060, for severe long-term pain in adults. It is for people who need a drug pumped into the fluid around the spinal cord, and who cannot take other treatments or got no relief from them. That pump into the spinal fluid is the only approved way to give it. The label carries a boxed warning, the FDA's strongest kind, for severe mental health symptoms and problems with brain and nerve function.
2 effects reported, 2 unwanted, by people using it, not a trial
Goal pages: Injury, healing and recovery, Bone and joints
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Ziconotide is a pain drug made from cone snail venom. It is only given by a pump under the skin that drips it into the spinal fluid. It is a last resort for severe long-term pain. There is no pill or shot version.
What people take it for
- Severe long-term pain when nothing else works.
- Pain relief without opioids.
What studies in people showed
In 255 people with pain not caused by cancer, pain fell 31.2 percent on the drug and 6.0 percent on a dummy. Side effects forced a dose cut partway through. In 111 people with cancer or AIDS pain, pain scores fell 53.1 percent on the drug and 18.1 percent on a dummy. In safety data from 1254 adults, dizziness, nausea, confusion and jerky eye movements each hit at least a quarter. It carries the FDA's strongest warning for mental and nerve problems.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- Dizziness, nausea, confusion and jerky eye movements each hit at least a quarter of patients in the safety data.
- The label warns of serious mental symptoms and nerve problems.
Where these come from: We have no user reports. The side effects are from the safety data and studies on this page.
My bottom line
A real drug for a small group of people in real pain. It has nothing to do with peptides sold online. If anyone offers you a vial, walk away.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Ziconotide has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Pain111 people · 2 studies
35 of the 36 indexed goals have no study of any kind behind Ziconotide
No study in people, animals or cells on this page reports a result for these. That does not prove Ziconotide does nothing for them. It does mean anything you have heard about Ziconotide and one of these did not come from a study cited here.
Show full evidence
What is Ziconotide?
Ziconotide is a pain drug made from cone snail venom, approved in 2004 for severe long-term pain. It only works when a pump implanted under the skin drips it into the spinal fluid. It carries the FDA's strongest warning, for serious mental and nerve side effects. In a study of 111 people with cancer or AIDS pain, pain scores fell 53.1 percent on the drug and 18.1 percent on a dummy. There is no pill, shot or cream version, and there cannot be one.
Ziconotide is a man-made copy of a small protein, 25 building blocks long, from the venom of a sea snail called Conus magus. The FDA approved it in December 2004 for adults with severe long-term pain. They must need a spinal pump, and other treatments must have failed them or been too hard to take. That includes strong pain pills, add-on drugs and morphine given into the spine. Every part of that sentence is a limit.
How it gets in is the first thing to understand. Ziconotide only works when it goes straight into the fluid around the brain and spinal cord. In practice that means a pump implanted under the skin, with a thin tube running into the spinal canal. The drug cannot get from the blood into the brain. So a pill, a shot under the skin or a skin patch would do nothing, and none exists.
Two studies with a dummy group supported the approval. One was in cancer and AIDS pain. The other was in long-term pain not caused by cancer. Both worked on a pain rating scale. In the second, side effects forced the team to cut the dose partway through. The starting dose dropped from 0.4 to 0.1 micrograms an hour, and the top dose from 7.0 to 2.4. The authors blame the side effects in that study on the first, higher doses.
Safety is the main limit, not a footnote. In safety data pooled from 1254 adults, dizziness, nausea, confusion and jerky eye movements each hit at least a quarter of patients. The label carries the FDA's strongest warning, for serious mental symptoms and nerve problems. It tells doctors not to use it in anyone with a past of psychosis.
Ziconotide shows up in consumer peptide writing as proof of what peptides can do. It is worth being blunt about why that fails. This is a last-resort hospital treatment. It needs surgery to fit a device, a strong warning label and specialist checks. It has nothing to do with a vial bought online.
How does Ziconotide work?
It blocks one type of calcium channel, called N-type, on the nerve endings that carry pain into the spinal cord. With calcium blocked, those nerve endings cannot release the chemicals that pass the pain signal on. This has nothing to do with opioids. Ziconotide does not touch opioid receptors. It does not build tolerance the way opioids do, and it is not linked to slowed breathing or addiction. The same action explains the mental and nerve side effects. These calcium channels are not only in pain pathways, and the drug sits in the fluid that bathes the whole brain and spinal cord.
What have studies in people found about Ziconotide?
Two studies with a dummy group back the approval. Both worked on a pain rating scale. Everyone in them had already failed other treatments, including morphine into the spine. A later review pooled three studies of ziconotide alone. People on the drug had 2.77 times the odds of responding, and the review flagged the side effects.
- Long-term pain not caused by cancer, 255 people over six days: pain scores fell 31.2 percent on the drug and 6.0 percent on the dummy.
- Cancer and AIDS pain, 111 people: pain scores improved 53.1 percent on the drug and 18.1 percent on the dummy.
- Both studies had to cut the dose or change the plan because of side effects. That is unusual, and the published papers say so.
- Pooled safety data from 1254 adults: 662 years of use added together, 193 days of treatment on average, and an average final dose of 17.6 micrograms a day.
- Side effects in at least a quarter of patients: dizziness, nausea, confusion and jerky eye movements.
What this does not tell you: Everyone in these studies had a spinal pump and had already failed normal pain treatment. So the results say nothing about what ziconotide would do in anyone else, and there is no other way to give it to test that. Both studies measured pain on a rating scale over days to weeks. They did not measure daily function, long-term opioid use, or quality of life. The review authors say plainly that flaws in the studies limit trust in the pooled result.
The state of the research
Ziconotide is in this archive for one reason. Marketing uses it as proof that peptide drugs work, and it almost always leaves out the facts that make it a hospital drug.
Those facts are: a pump implanted by surgery, the FDA's strongest warning for mental and nerve problems, side effects bad enough that both main studies changed their doses partway through, and a molecule that does nothing unless it goes straight into spinal fluid.
The science story really is remarkable. A venom from a hunting sea snail became a licensed pain drug that works nothing like an opioid. That story is not evidence for anything sold to consumers.
The evidence, in charts
Fig. 1a · how many people
111people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| JAMA 2004 | 111 | 100% |
The whole total is one study of 111. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 1 more study in people gives no headcount and is not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
2 of 3 sources here are studies in people. The rest is not.
- Study in people · done in people267%
- Review of studies · sums up other studies133%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 3 different years, 2004 to 2017, counted from the list of sources on this page. The newest source on file is from 2017, more than five years ago. Research on it may have gone quiet.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- About 2639 Da. Twenty five amino acids with three disulfide bridges.
- Half-life
- About 4.6 hoursShort, 1 to 6 hours
- Chain length
- None on file
Half-life as stated on file: About 4.6 hours in cerebrospinal fluid after intrathecal administration, with a reported range of roughly 2.9 to 6.5 hours. Clearance from the cerebrospinal fluid approximates the normal turnover rate of that fluid.
No amino acid sequence is on file for Ziconotide, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2004Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial
Ziconotide clearly relieved severe pain that nothing else was touching. 111 people with cancer or AIDS, aged 24 to 85, got either the drug or a dummy into the fluid around the spinal cord, and nobody involved knew which. Pain scores dropped by about half on the drug and by under a fifth on the dummy. Just over half the treated group got moderate to complete relief, against about one in six. The trial hit the target it was built to hit.
Double-blind, placebo-controlled, 32 centres in the United States, Australia and the Netherlands, 111 patients aged 24 to 85 randomised 2 to 1. Mean percentage improvement in the visual analogue scale of pain intensity was 53.1 percent (95 percent CI 44.0 to 62.2) with ziconotide versus 18.1 percent (95 percent CI 4.8 to 31.4) with placebo, P below 0.001. Moderate to complete pain relief in 52.9 percent versus 17.5 percent. Primary endpoint met.
- Study in people2006Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial
The drug worked for long term pain not caused by cancer, and the dose had to be cut mid trial to make it bearable. 255 hospital inpatients got ziconotide or a dummy into the spinal fluid over six days. Pain fell by about a third on the drug and by a twentieth on the dummy. Partway through, side effects forced the team to drop the starting dose fourfold and the ceiling by two thirds. It hit the target it was built to hit, but not at its original doses.
255 inpatients, 169 on ziconotide and 86 on placebo, treated over six days. Mean percent reduction in the visual analogue scale of pain intensity was 31.2 percent versus 6.0 percent. The protocol was amended during the trial, cutting the starting dose from 0.4 to 0.1 micrograms per hour and the maximum from 7.0 to 2.4 micrograms per hour, because of adverse events. The primary endpoint was met but at the original dosing the tolerability was not acceptable.
- Review of studies2017Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials
A review that pooled three studies of ziconotide given alone. People on the drug had 2.77 times the odds of responding compared with a dummy. But serious side effects were common enough that two of the three studies had to change their plans. The reviewers say flaws in the studies call the pooled result into question.
Three randomised trials of ziconotide monotherapy pooled in a random effects meta-analysis, giving an odds ratio for responders versus placebo of 2.77 (95 percent CI 1.37 to 5.59). The reviewers note that frequent serious adverse events caused two of the three studies to revise their protocols, and they raise methodological concerns that they say call the validity of the pooled result into question.
Where to buy Ziconotide
Ziconotide is an approved medicine. The approved product comes from a pharmacy, with a prescription. The vials below are sold “for research” and are not the approved drug.
No seller we track lists Ziconotide yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has Ziconotide been tested in people?
Yes. 111 people given it across 2 completed trials cited here, 0 of which found nothing. Ziconotide is a pain drug made from cone snail venom, approved in 2004 for severe long-term pain.
What is the Ziconotide dosage?
Approved medicine. No human dose established for unlabelled uses. Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose. FDA-approved on 28 December 2004 under NDA 021060, for severe long-term pain in adults. It is for people who need a drug pumped into the fluid around the spinal cord, and who cannot take other treatments or got no relief from them. That pump into the spinal fluid is the only approved way to give it. The label carries a boxed warning, the FDA's strongest kind, for severe mental health symptoms and problems with brain and nerve function.
Is Ziconotide FDA-approved?
FDA-approved on 28 December 2004 under NDA 021060, for severe long-term pain in adults. It is for people who need a drug pumped into the fluid around the spinal cord, and who cannot take other treatments or got no relief from them. That pump into the spinal fluid is the only approved way to give it. The label carries a boxed warning, the FDA's strongest kind, for severe mental health symptoms and problems with brain and nerve function.
Can I get ziconotide as an injection or a tablet?
No, and you never will. It cannot get from the blood into the brain. So it only works when dripped straight into the spinal fluid through a thin tube and an implanted pump. There is no pill, shot, drip into a vein or cream. Any vial sold as ziconotide outside a hospital pharmacy is not a usable medicine.
What is ziconotide approved for?
Severe long-term pain in adults who need a spinal pump, and who could not take or got no help from other treatment. That includes strong pain pills, add-on drugs and morphine into the spine. It is a last resort, not a first or second choice.
Is it addictive like an opioid?
It does not act on opioid receptors. So it does not cause opioid tolerance, dependence or slowed breathing. That is the main reason doctors use it. The trade-off is a different, serious problem. Dizziness, nausea, confusion and jerky eye movements each hit at least a quarter of patients. The label carries the FDA's strongest warning for serious mental symptoms and nerve problems.
How well does it actually work?
In the cancer and AIDS pain study, pain scores fell 53.1 percent on the drug and 18.1 percent on the dummy. 52.9 percent of patients got moderate to complete relief, against 17.5 percent. In pain not caused by cancer the gap was smaller, 31.2 percent against 6.0 percent. Both are short-term ratings on a pain scale, in people who had already failed everything else.
Is it related to any peptide sold online?
No. It shares the word peptide and nothing else. Ziconotide is one exact chain of 25 building blocks with three internal links, made to drug-factory standards. It is given through an implanted device, with a specialist in charge.